PDF Cover

Iomeprol Market

Iomeprol Market

The market for Iomeprol was estimated at $257.60 million in 2024; it is anticipated to increase to $367 million by 2030, with projections indicating growth to around $494 million by 2035.

Report ID:DS1806046
Author:Debadatta Patel - Senior Consultant
Published Date:April 2025
Datatree
Life Science
Other Healthcare
Iomeprol
Share
Report Summary
Table of Contents
Methodology
Market Data

Global Iomeprol Market Outlook

Revenue, 2024 (US$M)

$258M

Forecast, 2034 (US$M)

$465M

CAGR, 2024 - 2034

6.1%
The Iomeprol industry revenue is expected to be around $273.3 million in 2025 and expected to showcase growth with 6.1% CAGR between 2025 and 2034. The continual growth of the Iomeprol market is underpinned by several key factors. Chief among these is the persistent demand for improved contrast agents in medical imaging, coupled with an increasing prevalence of chronic and lifestyle-oriented diseases, which necessitate frequent radiographic examinations. Contributing to this upward trajectory is the emergence of more advanced imaging technologies, which, in turn, amplify the necessity for Iomeprol. Furthermore, the active engagement of pharmaceutical companies in research and development activities to enhance the efficiency of contrast agents bodes well for the sustained relevance and promising prospects of this market.

Iomeprol, a nonionic monomer contrast medium, is renowned for its low osmolality and high stability, which translates to minimal side effects and reactions. Predominantly utilized in angiographic procedures and computed tomography (CT) scans, it allows for superior visualization of blood vessels and internal body structures. The substances use in myelography and urography procedures is also noteworthy.

iomeprol market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034

Market Key Insights

  • The Iomeprol market is projected to grow from $257.6 million in 2024 to $465 million in 2034. This represents a CAGR of 6.1%, reflecting rising demand across Diagnostic Imaging, Urologic Examinations and Vascular Interventions.
  • Bracco S.p.A., Guerbet Group, GE Healthcare are among the leading players in this market, shaping its competitive landscape.
  • U.S. and Germany are the top markets within the Iomeprol market and are expected to observe the growth CAGR of 4.0% to 5.9% between 2024 and 2030.
  • Emerging markets including Indonesia, Brazil and South Africa are expected to observe highest growth with CAGR ranging between 7.0% to 8.4%.
  • Transition like Emergence of Digital Technology is expected to add $30.9 million to the Iomeprol market growth by 2030
  • The Iomeprol market is set to add $208 million between 2024 and 2034, with manufacturer targeting Angiography & Urography Imaging Modality projected to gain a larger market share.
  • With Rising demand in diagnostic procedures, and Innovation in contrast media, Iomeprol market to expand 81% between 2024 and 2034.
iomeprol market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032

Opportunities in the Iomeprol

Strategic collaborations with hospitals and healthcare institutes can offer a vast for Iomeprol. By partnering with such institutions, Iomeprol can solidify its presence in the market, thereby enhancing distribution and boosting overall sales.

Growth Opportunities in North America and Europe

North America Outlook

As a leading region in the global healthcare market, North America presents significant opportunities for Iomeprol, a commonly used contrast agent in imaging procedures. The dominant presence of pharmaceutical enterprises and advanced healthcare infrastructure in this region significantly drives the demand for Iomeprol. Furthermore, the regions focus on technological advancements in diagnostic procedures, the increasing prevalence of chronic diseases, and the aging population are other crucial drivers within the sector. However, the market is also characterized by intense competition, with several global players vying for a substantial market share, mitigating risks associated with price wars and patent expiry.

Europe Outlook

While Europe stands as the second largest market for Iomeprol, its growth can be attributed to the strong prevalence of public health programs and sustained government funding. From a market perspective, the escalating demand for non-invasive diagnostic techniques and therapeutics paired with the rise in cardiovascular ailments and disorders significantly propels the growth opportunities of Iomeprol within the region. Despite this upward trajectory, Europe faces stringent regulatory procedures that pose challenges for product approval. However, the robust presence of key market players and continual product innovations have kept the competition healthy and dynamic. The continents drive to maintain high-quality healthcare standards alongside a growing geriatric population further underlines its market potential for Iomeprol.

Market Dynamics and Supply Chain

01

Driver: Rising Demand in Diagnostic Procedures, and Emergence of Tailored Formulations

The widespread use of Iomeprol in medical imaging particularly in X-rays and CT scans underlies its increasing demand. Given the escalating prevalence of diseases requiring diagnostic procedures, Iomeprol use as a contrast agent is also anticipated to grow exponentially. The introduction of tailored formulations of Iomeprol for specific applications is also an emerging trend. This can also be seen in the varied concentrations of Iomeprol developed for differents of medical imaging procedures. It bodes well for the market growth as it caters to the precise needs of healthcare professionals and patients.
The market for Iomeprol is also spurred by continuous technological advancements in contrast media. Iomeprol, with its excellent tolerability and lower risk of kidney damage, leads the curve in non-ionic contrast media, which is also a growth sector within the industry.
02

Restraint: High Costs of Production

The manufacturing process of Iomeprol, a non-ionic, iso-osmolar contrast agent, often involves complex synthesis techniques and stringent quality control, resulting in a significant increase in production expenses. These high costs, in turn, impact the price point of the final product, potentially deterring price-sensitive buyers, thereby restraining market growth.
03

Opportunity: Technological Innovations and Emerging Markets

The advent of innovative technologies in the field of radiology presents a significant for the growth of Iomeprol. As contrast agents become more essential in imaging procedures, the use of Iomeprol, a nonionic iodinated contrast medium, is set to increase due to its favorable safety profile, and reliable imaging results.
Emerging economies such as India, Brazil, and China are witnessing a surge in healthcare infrastructure. This surge combined with the increasing prevalence of diseases requiring imaging diagnosis opens up a new consumer base for Iomeprol.
04

Challenge: Regulatory Hurdles

Governments across the globe have put stringent guidelines in place for pharmaceuticals like Iomeprol. While these regulations are essentially intended to ensure the safety and efficacy of such products, the process of obtaining necessary approvals can be both time-consuming and costly, acting as a significant barrier for new entrants as well as existing market players. These regulatory hurdles can delay the launch of products, directly affecting the market dynamics, and serve as a major obstacle to the growth of the Iomeprol market.

Supply Chain Landscape

1
Raw Material Procurement

BASF SE

Dow Chemical Company

2
Drug Synthesis

Sanofi S.A.

AstraZeneca

3
Formulation & Packaging

Bayer AG

Merck KGaA

4
Market Distribution

Novartis AG

Pfizer Inc

*The illustration highlights the key stakeholders within the supply chain ecosystem.

Applications of Iomeprol in Diagnostic Imaging, Urologic Examinations & Vascular Interventions

Diagnostic Imaging

Iomeprol is principally used in diagnostic imaging as an X-ray contrast agent. It enhances the visibility of certain internal structures during radiographic procedures, aiding clinicians in making precise diagnoses. Top players leveraging Iomeprol in this domain include renowned pharmaceutical corporations boasting a strong market position due to both their innovative imaging technologies and proven safety record.

Vascular Interventions

Iomeprol also sees prominent use in vascular interventions. Its role here is to enhance the visualization of blood vessels during endovascular procedures, playing a critical role in interventional cardiology and radiology. Leading companies in this sector have a marked competitive advantage, thanks to their dedicated focus on patient safety, alongside the strategic use of Iomeprol.

Urologic Examinations

Lastly, Iomeprol is an essential component in urologic examinations, increasing the contrast in urinary structures to assist in diagnosing renal conditions. This application has attracted market leaders who resort to leveraging the high-quality imaging capbilities of Iomeprol to achieve diagnostic precision, thereby elevating their market presence.

Recent Developments

December 2024

Pharmaceutical giant Bracco SpA announced a breakthrough innovation in the formulation of Iomeprol, resulting in improved patient tolerance and significantly reduced side effects.

October 2024

The FDA expanded the approved use of Iomeprol for diagnostic imaging in pediatrics, creating opportunities for the product in a new patient segment. This approval came after rigorous clinical trials by Bayer AG on the safety and effectiveness of Iomeprol in young patients.

July 2024

GE Healthcare unveiled their advanced processing methods for Iomeprol, which reduced its manufacturing cost and time, enhancing its market viability and affordability.

Iomeprol, an advanced iodinated contrast medium, has made substantial progress in the medical imaging market in recent times. This non-ionic contrast agent, employed in procedures like angiography and computed tomography, has been recognized for its distinguished radiographic performance. Significantly, Iomeprols market share has witnessed a sizable increase under the ongoing digital transformation within the healthcare sector.

Impact of Industry Transitions on the Iomeprol Market

As a core segment of the Other Healthcare industry, the Iomeprol market develops in line with broader industry shifts. Over recent years, transitions such as Emergence of Digital Technology and Focus on Ecofriendly Manufacturing have redefined priorities across the Other Healthcare sector, influencing how the Iomeprol market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Emergence of Digital Technology

The adoption of digital technology has had a profound impact on the Iomeprol industry. Modern technologies are revolutionizing the ways medical practitioners access contrast agents like Iomeprol for diagnostic procedures. Digitization, IOT , and AI platforms are facilitating realtime monitoring of supply chain processes, leading to streamlined operations and reduced waste. This digital transition has not only resulted in improved operational efficiency, but is also setting a new standard in the healthcare industry, encouraging other sectors to follow suit. This industry transition is expected to add $30.9 million in the industry revenue between 2024 and 2030.
02

Focus on Ecofriendly Manufacturing

Pressure from governmental bodies and environmental groups has led to a shift in the production methods of Iomeprol towards greener, more sustainable methods. Recent strides in chemical synthesis have allowed for the creation of this radiocontrast agent using procedures with reduced byproducts and minimal environmental impact. This shift towards ecofriendly manufacturing is starting to reshape theindustry'simpact on the environment and has set a precedent for other pharmaceutical products to follow similar sustainable approaches in production.

Related Reports

Loading related reports...